tbuckley/cabot-search huggingface dataset:
Abstract PO-072: Doctors and nurses during COVID19 pandemic: A different perception of cancer care
Authors: Lucia Bastianelli, Filippo Merloni, Nicoletta Ranallo, Luca Cantini, Lorenzo Mariotti, Alessandra Lucarelli, Zelmira Ballatore, Rossana Berardi
Journal: Clinical Cancer Research (2020)

Abstract Background: The spread of coronavirus disease brought the need to reorganize clinical activity in oncology. Cancer patients are very vulnerable, and it is well known that their treatment has to be strictly planned. The most critical considerations still relate to the entry of the virus into hospitals, the heart of health care, where cancer patients are protected. Instead, during the COVID19 pandemic the oncologic department had to limit access to care to protect patients from a more dangerous disease for them, witnessing a paradox of health care. This brought with it worries in oncologic health care professionals in replanning activities in order to guarantee therapeutic continuity and quality of care. It is well known that physicians and nurses have different role concepts and role expectations. The purpose of our study was to investigate doctors’ and nurses' perception of cancer patient reorganization during the COVID19 pandemic in a sample of Italian health care professionals in oncology. Methods: We submitted a survey to oncologic health care workers (physicians and nurses) of Italian National Health Care System during the pandemic to investigate clinical activity reorganization and cancer patient management through 12 closed questions. The survey promoted by Clinica Oncologica, AOU Riuniti di Ancona-Università Politecnica delle Marche was electronic and anonymous. Results: A total of 383 oncology health workers completed the survey, 60 nurses (15%) and 323 physicians (85%). 60% of interviewed physicians perceived qualitatively lower than usual the therapeutic path of patients taken in charge in this historical moment, while 45% of nurses declared it was the same (P&amp;lt;0.01). The continuity of the multidisciplinary team was defined as guaranteed for 68% of oncologists, while almost 40% of nurses declared to not know it. Almost all physicians (95%) answered that their clinical activity was reorganized, compared to a lower portion of nurses (80%) who replanned their care role (p&amp;lt;0.01). Deferring treatments caused fear and anxiety in 62% of physicians and 46% of nurses (P=0.027). Conclusion: The survey underlined the need to integrate skills and involve all professional figures in planning cancer patients’ treatment to guarantee optimal therapeutic strategies and a global take in charge in all its details, even during emergencies. Citation Format: Lucia Bastianelli, Filippo Merloni, Nicoletta Ranallo, Luca Cantini, Lorenzo Mariotti, Alessandra Lucarelli, Zelmira Ballatore, Rossana Berardi. Doctors and nurses during COVID19 pandemic: A different perception of cancer care [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr PO-072.
A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies
Authors: Grzegorz S. Nowakowski, Lori A. Leslie, Erel Joffe, Allison C. Rosenthal, Matthew A. Lunning, Krish Patel, Monica Mead, Daniel J. Landsburg, Timothy S. Fenske, Radhakrishnan Ramchandren, Praveen Ramakrishnan Geethakumari, Alan Skarbnik, Elizabeth Martinez, Christopher Lieberman, Reinhard von Roemeling, Han W. Tun
Journal: Blood (2020)
Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone
Authors: Marco Basset, Christoph Kimmich, Tobias Dittrich, Kaya Veelken, Hartmut Goldschmidt, Dirk Hose, Anja Seckinger, Anna Jauch, Carsten Mueller-Tidow, Ute Hegenbart, Stefan Schönland
Journal: Blood (2020)
Multiplex CRISPR/Cas9 Genome Editing Targeting the BCL11A/HBG Axis Maximizes Fetal Hemoglobin Reinduction but Generates Chromosomal Translocations Which Persist In Vivo
Authors: Clare Samuelson, Olivier Humbert, Stefan Radtke, Haiying Zhu, Mallory J Llewellyn, Emily Fields, Savannah Cook, Meei-Li W Huang, Olivier Negre, Keith Jerome, Hans-Peter Kiem
Journal: Blood (2020)
Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy
Authors: Marius Bill, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Christopher J. Walker, Dimitrios Papaioannou, James S. Blachly, Shelley Orwick, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Andrew J Carroll, Ramiro Garzon, Richard M. Stone, John C. Byrd, Clara D. Bloomfield, Ann-Kathrin Eisfeld
Journal: Blood (2020)
Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial
Authors: Amy C.M. Musiek, Sean Whittaker, Steven M. Horwitz, Martine Bagot, Auris Huen, David C. Fisher, Paul Haun, Maarten H. Vermeer, Takahiro Ito, Karen Dwyer, Fiona Herr, Youn H. Kim
Journal: Blood (2020)
The Enhanced Functionality of Low-Affinity CD19 CAR T Cells Is Associated with Activation Priming and Polyfunctional Cytokine Phenotype
Authors: Ilaria M. Michelozzi, Eduardo Gomez-Castaneda, Ruben V.C. Pohle, Ferran Cardoso Rodriguez, Jahangir Sufi, Pau Puigdevall, Meera Subramaniyam, Si Wei Wu, Aleks Guvenel, Sara Ghorashian, Martin Pule, Christopher J. Tape, Sergi Castellano, Persis J Amrolia, Alice Giustacchini
Journal: Blood (2020)
Remote postconditioning ameliorates stroke damage by preventing let-7a and miR-143 up-regulation
Authors: Antonio Vinciguerra, Pasquale Cepparulo, Serenella Anzilotti, Ornella Cuomo, Valeria Valsecchi, Salvatore Amoroso, Lucio Annunziato, Giuseppe Pignataro
Journal: Theranostics (2020)

Remote limb ischemic postconditioning (RLIP) is a well-established neuroprotective strategy able to protect the brain from a previous harmful ischemic insult through a sub-lethal occlusion of the femoral artery. Neural and humoral mechanisms have been proposed as mediators required to transmit the peripheral signal from limb to brain. Moreover, different studies suggest that protection observed at brain level is associated to a general genetic reprogramming involving also microRNAs (miRNAs) intervention. Methods: Brain ischemia was induced in male rats by transient occlusion of the middle cerebral artery (tMCAO), whereas RLIP was achieved by one cycle of temporary occlusion of the ipsilateral femoral artery after tMCAO. The expression profile of 810 miRNAs was evaluated in ischemic brain samples from rats subjected either to tMCAO or to RLIP. Among all analyzed miRNAs, there were four whose expression were upregulated after stroke and returned to basal level after RLIP, thus suggesting a possible involvement in RLIP-induced neuroprotection. These selected miRNAs were intracerebroventricularly infused in rats subjected to remote ischemic postconditioning, and their effect was evaluated in terms of brain damage, neurological deficit scores and expression of putative targets. Results: Twenty-one miRNAs, whose expression was significantly affected by tMCAO and by tMCAO plus RLIP, were selected based on microarray microfluidic profiling. Our data showed that: (1) stroke induced an up-regulation of let-7a and miR-143 (2) these two miRNAs were involved in the protective effects induced by RLIP and (3) HIF1-α contributes to their protective effect. Indeed, their expression was reduced after RLIP and the exogenous intracerebroventricularly infusion of let-7a and miR-143 mimics prevented neuroprotection and HIF1-α overexpression induced by RLIP. Conclusions: Prevention of cerebral let-7a and miR-143 overexpression induced by brain ischemia emerges as new potential strategy in stroke intervention.
Using rapid point-of-care tests to inform antibiotic choice to mitigate drug resistance in gonorrhoea
Authors: Carolin Vegvari, Yonatan H Grad, Peter J White, Xavier Didelot, Lilith K Whittles, Nicole E Scangarella-Oman, Fanny S Mitrani-Gold, Etienne Dumont, Caroline R Perry, Kim Gilchrist, Mohammad Hossain, Tatum D Mortimer, Roy M Anderson, David Gardiner
Journal: Eurosurveillance (2020)

Background The first cases of extensively drug resistant gonorrhoea were recorded in the United Kingdom in 2018. There is a public health need for strategies on how to deploy existing and novel antibiotics to minimise the risk of resistance development. As rapid point-of-care tests (POCTs) to predict susceptibility are coming to clinical use, coupling the introduction of an antibiotic with diagnostics that can slow resistance emergence may offer a novel paradigm for maximising antibiotic benefits. Gepotidacin is a novel antibiotic with known resistance and resistance-predisposing mutations. In particular, a mutation that confers resistance to ciprofloxacin acts as the ‘stepping-stone’ mutation to gepotidacin resistance. Aim To investigate how POCTs detecting Neisseria gonorrhoeae resistance mutations for ciprofloxacin and gepotidacin can be used to minimise the risk of resistance development to gepotidacin. Methods We use individual-based stochastic simulations to formally investigate the aim. Results The level of testing needed to reduce the risk of resistance development depends on the mutation rate under treatment and the prevalence of stepping-stone mutations. A POCT is most effective if the mutation rate under antibiotic treatment is no more than two orders of magnitude above the mutation rate without treatment and the prevalence of stepping-stone mutations is 1–13%. Conclusion Mutation frequencies and rates should be considered when estimating the POCT usage required to reduce the risk of resistance development in a given population. Molecular POCTs for resistance mutations and stepping-stone mutations to resistance are likely to become important tools in antibiotic stewardship.
A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML
Authors: Sameem Abedin, Guru Subramanian Guru Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Lyndsey Runaas, Karen-Sue Carlson, Alexandra M. Harrington, Ehab L. Atallah
Journal: Blood (2020)
The Prevalence of Lymphocytopenia Among Arab Population with Iron Deficiency Anemia an Experience from Qatar
Authors: Hussam A Almasri, Ashraf Tawfiq Soliman, Vincenzo Desanctis, Rita Wafik Ahmad, Mustafa A Al-Tikrity, Ruoa Alhashimy, Mohammad N Kloub, Majd M Aldwairi, Mahmoud S Eisa, Arwa E Alsaud, Mona M Babikir, Shaima Ahmed, Mohamed A Yassin
Journal: Blood (2020)
A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia
Authors: Aziz Nazha, Sudipto Mukherjee, Caitlin Siebenaller, Madeline Waldron, Eric Parsons, Jenna Thomas, Hetty E. Carraway, Dale Grabowski, Yihong Guan, Aaron T. Gerds, Bhumika J. Patel, Anjali S Advani, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2020)
Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRASG12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS
Authors: Iris Appelmann, Azam Salimi, Michael Huber, Mirle Schemionek, Margherita Vieri, Tim H Brümmendorf, John B. Patterson, Behzad Kharabi Masouleh
Journal: Blood (2020)
HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents
Authors: Joan Blade Creixenti, María-Victoria Mateos, Albert Oriol, Alessandra Larocca, Michele Cavo, Paula Rodríguez-Otero, Xavier Leleu, Maxim Norkin, Omar Nadeem, John W. Hiemenz, Hani Hassoun, Cyrille Touzeau, Adrián Alegre Amor, Agne Paner, Christopher Maisel, Amitabha Mazumder, Anastasios Raptis, Noemí Puig, Stojan Zavisic, Marcus Thuresson, Johan Harmenberg, Paul G. Richardson
Journal: Blood (2020)
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum
Authors: Stuart P. Weisberg, Thomas J. Connors, Yun Zhu, Matthew R. Baldwin, Wen-Hsuan Lin, Sandeep Wontakal, Peter A. Szabo, Steven B. Wells, Pranay Dogra, Joshua Gray, Emma Idzikowski, Debora Stelitano, Francesca T. Bovier, Julia Davis-Porada, Rei Matsumoto, Maya Meimei Li Poon, Michael Chait, Cyrille Mathieu, Branka Horvat, Didier Decimo, Krystalyn E. Hudson, Flavia Dei Zotti, Zachary C. Bitan, Francesca La Carpia, Stephen A. Ferrara, Emily Mace, Joshua Milner, Anne Moscona, Eldad Hod, Matteo Porotto, Donna L. Farber
Journal: Nature Immunology (2020)
Characterization of Abnormal Hemoglobins in the Blood Center of Rio Grande Do Norte, Brazil By High Performance Liquid Chromatography
Authors: Gustavo Henrique de Medeiros Oliveira, Aldair Sousa Paiva, Alessandra Suelen Jardim Silva, Lenilton Silva DA Silva Júnior, Hugo Henrique de Freitas Ferreira, Maria das Graças Pereira Araujo, Victor lima Soares, Frank Bahia, Rodrigo Villar Freitas, Taissa Moura Oliveira, Dany GKC Silva, Valéria SF Sales, Rodolfo DA Soares, Hugo Diogenes De Oliveira Paiva, Geraldo Barroso Cavalcanti
Journal: Blood (2020)
Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials
Authors: M. Lia Palomba, Monika P. Jun, Jacob Garcia, James Lymp, November McGarvey, Matthew Gitlin, Corey Pelletier, Andy Nguyen
Journal: Blood (2020)
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential
Authors: Dimitrios Strepkos, Mariam Markouli, Alexia Klonou, Athanasios G. Papavassiliou, Christina Piperi
Journal: Cancer Research (2020)

Abstract Epigenetic regulation of gene expression has been ultimately linked to cancer development, with posttranslational histone modifications representing attractive targets for disease monitoring and therapy. Emerging data have demonstrated histone lysine (K) methylation by methyltransferase SETDB1 as a common denominator of gene regulation in several cancer types. SETDB1 reversibly catalyzes the di- and trimethylation of histone 3 (H3) K9 in euchromatic regions of chromosomes, inhibiting gene transcription within these regions and promoting a switch from euchromatic to heterochromatic states. Recent studies have implicated aberrant SETDB1 activity in the development of various types of cancers, including brain, head and neck, lung, breast, gastrointestinal, ovarian, endometrial and prostate cancer, mesothelioma, melanoma, leukemias, and osteosarcoma. Although its role has not been fully elucidated in every case, most data point toward a pro-oncogenic potential of SETDB1 via the downregulation of critical tumor-suppressive genes. Less commonly, however, SETDB1 can also acquire a tumor-suppressive role, depending on cancer type and stage. Here we provide an updated overview of the cellular and molecular effects underlying SETDB1 activity in cancer development and progression along with current targeting strategies in different cancer types, with promising effects either as a standalone therapy or in conjunction with other therapeutic agents.
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis
Authors: Yuchuan Ding, Baozhen Huang, Yuan Wang, Jun Hou, Ying Chi, Zhixuan Zhou, Jianguo Li
Journal: Annals of the Rheumatic Diseases (2020)

Letters Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositisJuvenile dermatomyositis (JDM) is a rare systemic autoimmune vasculopathy characterised by weakness in proximal muscles and pathognomonic skin rashes. 1 Clinically, some patients are refractory to any available treatments or became steroids dependent. 2 The adverse reactions of long-term use of steroids are severe; therefore, more effective and safer medications are urgently needed.][5] Here, we want to share the JAKi using experiences of 25 refractory JDM cases who were diagnosed and classified according to Bohan and Peter's criteria and treated between November 2017 and May 2019.Written informed consents were obtained from the guardians of all patients before starting the treatment.Among 25 cases, 44% (11/25) patients were female, the mean age of onset was 4.6±3.3years and the mean age to start add-on JAKi treatment was 7.2±4.0years.The mean disease course of the 25 JDM patients before JAKi treatment is 21.0 months (range: 14.0-36.5).All cases are refractory JDMs, including 32% (8/25) ineffective patients and 68% (17/25) glucocorticoiddependent cases.After routine treatment fails, they received JAKi for 3-18 months as an off-label use.In subsequent JAKi treatment, 28% (7/25) used tofacitinib, and 72% (18/25) used ruxolitinib.In patients of <25 kg (n=11), the initial dosage was 2.5 mg twice daily, and in patients of ≥25 kg (n=14), the initial dosage was 5 mg twice daily, and one patient required the maximum dosage of 7.5 mg twice daily.The 25 patients were followed for a median of 7.0 months (range: 3-21 months).Ninety-six per cent (24/25) had rash when on August 20, 2023 by guest.
Abstract 423: Caveolin-3 Enriches and Dynamically Interacts With Swell1
Authors: Daniel G Turner, Leonid Tyan, Sami Stroebel, Frank Deguire, Di Lang, Alexey Glukhov
Journal: Circulation Research (2020)

Caveolae are small (50-100nm) membrane invaginations formed by caveolin proteins enriched with cholesterol and lipids. Caveolae play a crucial role in mechanoprotection and mechano-electrical transduction by buffering membrane tension and facilitating activation of mechanosensitive ion channels, including a recently discovered swelling-activated chloride channel SWELL1 (also known as LRRC8A). However, the dynamic relationship between the muscle-specific caveolar scaffolding protein caveolin-3 (Cav3) and SWELL1 is poorly understood. The objective of this study was to determine how Cav3 interacts with SWELL1 channels and modulates their activity during mechano-electrical transduction. In HEK 293 cells transfected with Cav3, co-immunoprecipitation analysis recapitulated cardiac data showing association between SWELL1 and Cav3. Using transiently expressed Cav3-GFP and SWELL1-mCherry fusion proteins in HEK293 cells, we observed a high FRET efficiency between the two proteins in an isotonic (1T) solution, confirming their close (&lt;5nm) proximity. In a hypotonic solution (0.7T, mimicking cell stretch), FRET efficiency decreased two-fold. Furthermore, FRET efficiency decreased two-fold to control levels when incubated with methyl-beta cyclodextrin, a cholesterol solubilizer. These data suggest that the relationship between Cav3 and SWELL1 is dependent on membrane mechanical tension and caveolae lipid raft integrity. Interestingly, in transfected cells, SWELL1 protein expression and whole cell swelling-activated chloride current ( I Cl,swell ) were increased four-fold and two-fold, respectively, while mRNA expression was reduced two-fold. This may indicate that caveolae formed by Cav3 expression enrich for SWELL1 and increase their half-life, thus requiring lower mRNA availability despite higher protein expression. Our findings indicate a close dynamic interplay between Cav3 and SWELL1, with a strong regulatory action of Cav3 on I Cl,swell activity. Given that I Cl,swell increases and interprotein FRET efficiency decreases in hypotonic solution, it is likely that Cav3 inhibits the activation of SWELL1 similarly to its known inhibition of nitric oxide synthase.
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
Authors: Aimaz Afrough, Leonard C Alsfeld, Ruby Delgado, Uday R. Popat, Partow Kebriaei, Betul Oran, Neeraj Saini, Samer A. Srour, Chitra Hosing, Elisabet E. Manasanch, Hans C. Lee, Gregory P. Kaufman, Krina K. Patel, Robert Z. Orlowski, Chelsea C. Pinnix, Bouthaina S. Dabaja, Sheeba K. Thomas, Donna M. Weber, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash, Qaiser Bashir
Journal: Blood (2020)
Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution
Authors: Katherine P Baker, Roman M Shapiro, Carol Reynolds, Benedetta Rambaldi, Augustine Weber, Matilde Dal Boni, John Koreth, Corey Cutler, Joseph H. Antin, Vincent T. Ho, Sarah Nikiforow, Mahasweta Gooptu, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Rizwan Romee
Journal: Blood (2020)
Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia
Authors: Eli Muchtar, Amber Koehler, Michael J Johnson, Kari G Rabe, Wei Ding, Timothy G. Call, Jose F. Leis, Saad S. Kenderian, Suzanne R. Hayman, Yucai Wang, Paul J. Hampel, Mathew Holets, Heather C Darby, Susan L. Slager, Neil E. Kay, Jennifer A Whitaker, Myron Levin, Richard Kennedy, Adriana Weinberg, Sameer A. Parikh
Journal: Blood (2020)
The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia
Authors: Titouan Cazaubiel, Laure Buisson, Sabrina Maheo, Laura Do Souto Ferreira, Romain Lannes, Aurore Perrot, Cyrille Hulin, Hervé Avet-Loiseau, Jill Corre
Journal: Blood (2020)
Role of Oligoadenylate Synthetases in Myeloid Neoplasia
Authors: Metis Hasipek, Yihong Guan, Dale Grabowski, Xiaorong Gu, Yogenthiran Saunthararajah, Robert Silverman, George R Stark, Jaroslaw Maciejewski, Babal K. Jha
Journal: Blood (2020)
Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients
Authors: Shaadi Mehr, Daniel Auclair, Mark Hamilton, Leon Rozenblit, Hearn Jay Cho, Lijun Yao, Reyka G Jayasinghe, Manoj Bhasin, Steven E. Labkoff, Taxiarchis Kourelis, Madhav V. Dhodapkar, Deon Doxie, Sacha Gnjatic, Cassandra Dewitt, Sergey Miron
Journal: Blood (2020)
Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial
Authors: Nina Shah, Michel Delforge, Jesús F. San-Miguel, Kaitlyn B. Bertin, Muna J Tahir, Hannah B. Lewis, Julie Wang, Julia Braverman, Timothy B. Campbell, Devender Dhanda, Nikhil C. Munshi
Journal: Blood (2020)
TLR, RAGE, and HMGB1 in the Inflammatory Response in Ph(-) Myeloproliferative Neoplasm
Authors: Guanfang Shi, Kiron Nair, Preethi Ramachandran, Chi Chen, Ching Wong, Gardith Joseph, Vladimir Gotlieb, Maksim Liaukovich, Jen-Chin Wang
Journal: Blood (2020)
A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure
Authors: Aziz Nazha, Sudipto Mukherjee, Anjali S Advani, Madeline Waldron, Caitlin Siebenaller, Jenna Thomas, Eric Parsons, Hetty E. Carraway, Aaron T. Gerds, Bhumika J. Patel, Mikkael A. Sekeres
Journal: Blood (2020)